CRISPR

CRISPR2-mfrp

ID

ZDB-CRISPR-180816-2

Name

CRISPR2-mfrp

Previous Names

None

Target

mfrp (1)

Sequence

5' - GGGTAAGGCTTCGGGTGGTT - 3'

Disclaimer

Although ZFIN verifies reagent sequence data, we recommend that you conduct independent sequence analysis before ordering any reagent.

Note

targets exon 8

Genome Resources

None

Target Location

Constructs

No data available

Genomic Features

Genomic Feature	Affected Genomic Regions
mw78	mfrp
mw79	mfrp

Expression

Gene expression in Wild Types + CRISPR2-mfrp

No data available

Phenotype

Phenotype resulting from CRISPR2-mfrp

No data available

Phenotype of all Fish created by or utilizing CRISPR2-mfrp

Phenotype	Fish	Conditions	Figures
retinal pigmented epithelium mfrp expression absent, abnormal	mfrp^mw78/mw78	standard conditions	Fig. 2 from Collery et al., 2016
optokinetic behavior decreased occurrence, abnormal	mfrp^mw78/mw78	standard conditions	Fig. 8 from Collery et al., 2016
eye transverse plane decreased length, abnormal	mfrp^mw78/mw78	standard conditions	Fig. 3 from Collery et al., 2016
eye decreased size, abnormal	mfrp^mw78/mw78	standard conditions	Fig. 3 from Collery et al., 2016
retina decreased size, abnormal	mfrp^mw78/mw78	standard conditions	Fig. 4 from Collery et al., 2016
retinal pigmented epithelium folded, abnormal	mfrp^mw78/mw78	standard conditions	Fig. 4 from Collery et al., 2016
retinal neural layer folded, abnormal	mfrp^mw78/mw78	standard conditions	Fig. 4 from Collery et al., 2016
retinal inner nuclear layer macrophage decreased amount, abnormal	mfrp^mw78/+; w202Tg/w202Tg	chemical treatment by environment: metronidazole	Fig. 3 from Brandt et al., 2021
retinal outer nuclear layer macrophage decreased amount, abnormal	mfrp^mw78/+; w202Tg/w202Tg	chemical treatment by environment: metronidazole	Fig. 3 from Brandt et al., 2021
whole organism shortened, abnormal	mfrp^mw78/+; w202Tg/w202Tg	chemical treatment by environment: metronidazole	Fig. 4 from Brandt et al., 2021
retinal ganglion cell layer macrophage decreased amount, abnormal	mfrp^mw78/+; w202Tg/w202Tg	chemical treatment by environment: metronidazole	Fig. 3 from Brandt et al., 2021
retinal inner nuclear layer ab5-lcp1 labeling decreased amount, abnormal	mfrp^mw78/+; w202Tg/w202Tg	chemical treatment by environment: metronidazole	Fig. 3 from Brandt et al., 2021
eye decreased curvature, abnormal	mfrp^mw78/+; w202Tg/w202Tg	chemical treatment by environment: metronidazole	Fig. 4 from Brandt et al., 2021
retinal ganglion cell layer ab5-lcp1 labeling decreased amount, abnormal	mfrp^mw78/+; w202Tg/w202Tg	chemical treatment by environment: metronidazole	Fig. 3 from Brandt et al., 2021
retina macrophage ab5-lcp1 labeling decreased amount, abnormal	mfrp^mw78/+; w202Tg/w202Tg	chemical treatment by environment: metronidazole	Fig. 3 from Brandt et al., 2021
retina macrophage ab9-gfp labeling decreased amount, abnormal	mfrp^mw78/+; w202Tg/w202Tg	chemical treatment by environment: metronidazole	Fig. 3 from Brandt et al., 2021
retina macrophage decreased amount, abnormal	mfrp^mw78/+; w202Tg/w202Tg	chemical treatment by environment: metronidazole	Fig. 2 from Brandt et al., 2021
retinal inner nuclear layer ab9-gfp labeling decreased amount, abnormal	mfrp^mw78/+; w202Tg/w202Tg	chemical treatment by environment: metronidazole	Fig. 3 from Brandt et al., 2021
retinal outer nuclear layer cell division decreased frequency, abnormal	mfrp^mw78/+; w202Tg/w202Tg	chemical treatment by environment: metronidazole	Fig. 6 from Brandt et al., 2021
retinal ganglion cell layer ab9-gfp labeling decreased amount, abnormal	mfrp^mw78/+; w202Tg/w202Tg	chemical treatment by environment: metronidazole	Fig. 3 from Brandt et al., 2021
retina macrophage ab-4c4 labeling decreased amount, abnormal	mfrp^mw78/+; w202Tg/w202Tg	chemical treatment by environment: metronidazole	Fig. 2 from Brandt et al., 2021
retinal outer nuclear layer ab9-gfp labeling decreased amount, abnormal	mfrp^mw78/+; w202Tg/w202Tg	chemical treatment by environment: metronidazole	Fig. 3 from Brandt et al., 2021
retinal outer nuclear layer ab5-lcp1 labeling decreased amount, abnormal	mfrp^mw78/+; w202Tg/w202Tg	chemical treatment by environment: metronidazole	Fig. 3 from Brandt et al., 2021
sclera collagen fibril organization decreased process quality, exacerbated	mfrp^mw78/+; w202Tg/w202Tg	chemical treatment by environment: metronidazole	Fig. 7 from Brandt et al., 2021
sclera positive regulation of collagen binding decreased process quality, abnormal	mfrp^mw78/mw78; w202Tg/w202Tg	chemical treatment by environment: metronidazole	Fig. 8 from Brandt et al., 2021
whole organism shortened, abnormal	mfrp^mw78/mw78; w202Tg/w202Tg	chemical treatment by environment: metronidazole	Fig. 4 from Brandt et al., 2021
retina macrophage decreased amount, abnormal	mfrp^mw78/mw78; w202Tg/w202Tg	chemical treatment by environment: metronidazole	Fig. 2 from Brandt et al., 2021
retinal inner nuclear layer macrophage decreased amount, abnormal	mfrp^mw78/mw78; w202Tg/w202Tg	chemical treatment by environment: metronidazole	Fig. 3 from Brandt et al., 2021
retinal ganglion cell layer macrophage decreased amount, abnormal	mfrp^mw78/mw78; w202Tg/w202Tg	chemical treatment by environment: metronidazole	Fig. 3 from Brandt et al., 2021
retinal outer nuclear layer cell division decreased frequency, abnormal	mfrp^mw78/mw78; w202Tg/w202Tg	standard conditions	Fig. 6 from Brandt et al., 2021
retinal outer nuclear layer macrophage decreased amount, abnormal	mfrp^mw78/mw78; w202Tg/w202Tg	chemical treatment by environment: metronidazole	Fig. 3 from Brandt et al., 2021
retinal inner nuclear layer ab5-lcp1 labeling decreased amount, abnormal	mfrp^mw78/mw78; w202Tg/w202Tg	chemical treatment by environment: metronidazole	Fig. 3 from Brandt et al., 2021
eye decreased size, abnormal	mfrp^mw78/mw78; w202Tg/w202Tg	standard conditions	Fig. 4 from Brandt et al., 2021
eye decreased curvature, abnormal	mfrp^mw78/mw78; w202Tg/w202Tg	chemical treatment by environment: metronidazole	Fig. 4 from Brandt et al., 2021
retinal ganglion cell layer ab5-lcp1 labeling decreased amount, abnormal	mfrp^mw78/mw78; w202Tg/w202Tg	chemical treatment by environment: metronidazole	Fig. 3 from Brandt et al., 2021
retina macrophage ab9-gfp labeling decreased amount, abnormal	mfrp^mw78/mw78; w202Tg/w202Tg	chemical treatment by environment: metronidazole	Fig. 3 from Brandt et al., 2021
retinal inner nuclear layer ab9-gfp labeling decreased amount, abnormal	mfrp^mw78/mw78; w202Tg/w202Tg	chemical treatment by environment: metronidazole	Fig. 3 from Brandt et al., 2021
retina macrophage ab5-lcp1 labeling decreased amount, abnormal	mfrp^mw78/mw78; w202Tg/w202Tg	chemical treatment by environment: metronidazole	Fig. 3 from Brandt et al., 2021
retinal outer nuclear layer cell division decreased frequency, abnormal	mfrp^mw78/mw78; w202Tg/w202Tg	chemical treatment by environment: metronidazole	Fig. 6 from Brandt et al., 2021
retinal outer nuclear layer ab9-gfp labeling decreased amount, abnormal	mfrp^mw78/mw78; w202Tg/w202Tg	chemical treatment by environment: metronidazole	Fig. 3 from Brandt et al., 2021
retinal ganglion cell layer ab9-gfp labeling decreased amount, abnormal	mfrp^mw78/mw78; w202Tg/w202Tg	chemical treatment by environment: metronidazole	Fig. 3 from Brandt et al., 2021
retinal outer nuclear layer ab5-lcp1 labeling decreased amount, abnormal	mfrp^mw78/mw78; w202Tg/w202Tg	chemical treatment by environment: metronidazole	Fig. 3 from Brandt et al., 2021
sclera collagen fibril organization decreased process quality, abnormal	mfrp^mw78/mw78; w202Tg/w202Tg	standard conditions	Fig. 7 from Brandt et al., 2021
sclera collagen fibril organization decreased process quality, exacerbated	mfrp^mw78/mw78; w202Tg/w202Tg	chemical treatment by environment: metronidazole	Fig. 7 from Brandt et al., 2021
eye decreased size, abnormal	mfrp^mw78/mw78; w202Tg/w202Tg	chemical treatment by environment: metronidazole	Fig. 4 from Brandt et al., 2021
retina macrophage increased amount, abnormal	mfrp^mw78/mw78; w202Tg/w202Tg	standard conditions	Fig. 2 from Brandt et al., 2021

Citations